Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology, based on its proprietary technological platform DOS47, announces that the board of directors has granted 21,400,000 incentive stock options to directors, officers, employees and consultants of the Company pursuant to its equity compensation plan.
NR20240719_Grant of Stock Options